BIOMAT Database Logo BIOMAT Database Logo

[Combination chemotherapy of ifosfamide, cisplatin and vindesine for non-small cell lung cancer]. 1990

S Itami, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and N Mizunuma, and K Nakagawa
Dept. of Clinical Oncology, Cancer Institute Hospital.

Twenty patients with advanced non-small cell lung cancer were treated with a combination chemotherapy consisting of ifosfamide (IFX), cisplatin (CDDP) and vindesine (VDS). The treatment schedule was IFX 1.3 g/m2 i.v., on days 1-5, CDDP 20 mg/m2 i.v., on days 1-5, and VDS 3 mg/m2 i.v., on days 1 & 8, and, in principle, the regimen was repeated every 4 weeks. Of 19 evaluable patients, there were 1 CR, 7 PR, 10 NC and 1 PD, with an overall response rate of 42.1%. The median duration of responses was 7.45 months, and the median survival time of all patients was 13.2 months. The major toxicities occurring were hematologic toxicity, alopecia, gastrointestinal toxicity and peripheral neuropathy. Hematologic toxicity was severe and was judged to be dose limiting, but clinically manageable. These results indicate that this combination chemotherapy is active against non-small cell lung cancer and deserves further studies.

UI MeSH Term Description Entries
D007069 Ifosfamide Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Isofosfamide,Isophosphamide,Asta Z 4942,Holoxan,Iphosphamide,Iso-Endoxan,NSC-109,724,NSC-109724,Iso Endoxan,NSC 109,724,NSC 109724,NSC109,724,NSC109724
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response

Related Publications

S Itami, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and N Mizunuma, and K Nakagawa
Cisplatin, doxorubicin, cyclophosphamide, and vindesine combination chemotherapy for non-small cell lung cancer.
February 1982, Cancer treatment reports,
S Itami, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and N Mizunuma, and K Nakagawa
Cisplatin, ifosfamide and vindesine in the chemotherapy of non-small-cell lung cancer: a combination phase II study.
January 1990, Cancer chemotherapy and pharmacology,
S Itami, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and N Mizunuma, and K Nakagawa
[Combination chemotherapy consisting of ifosfamide and vindesine for non-small cell lung cancer in the elderly].
April 2000, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society,
S Itami, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and N Mizunuma, and K Nakagawa
[Chemotherapy of non-small cell bronchial cancer with ifosfamide in combination with cisplatin, etoposide or vindesine].
January 1988, Onkologie,
S Itami, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and N Mizunuma, and K Nakagawa
Phase II study of ifosfamide, cisplatin, and vindesine combination in advanced non-small cell lung cancer.
October 1991, Acta medica Okayama,
S Itami, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and N Mizunuma, and K Nakagawa
Cisplatin, vindesine and bleomycin (CVB) combination chemotherapy of advanced non-small cell lung cancer.
March 1983, Cancer,
S Itami, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and N Mizunuma, and K Nakagawa
Randomized phase II trial comparing two chemotherapy combinations for non-small cell lung cancer. Mitomycin, ifosfamide, and cisplatin versus vindesine, ifosfamide, and cisplatin.
August 1993, American journal of clinical oncology,
S Itami, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and N Mizunuma, and K Nakagawa
Combination chemotherapy with cisplatin, vindesine and mitomycin-C for advanced, inoperable non-small-cell lung cancer.
May 1992, The Medical journal of Australia,
S Itami, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and N Mizunuma, and K Nakagawa
Combination chemotherapy with ifosfamide, mitomycin, and cisplatin in advanced non-small cell lung cancer.
September 1987, Cancer treatment reports,
S Itami, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and N Mizunuma, and K Nakagawa
[Randomized trial of cisplatin plus ifosfamide versus cisplatin plus vindesine for non-small cell lung cancer (NSCLC)].
January 1992, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!